Canvuparatide for Hypoparathyroidism Study
This study is looking into a new treatment called canvuparatide for adults with hypoparathyroidism (HypoPT), a condition where your body doesn't make enough parathyroid hormone. Researchers want to see if weekly doses of canvuparatide are safe and effective compared to a placebo (an inactive substance). You might be able to join if you are at least 18 years old, have had HypoPT for at least 12 months, and meet certain requirements for your parathyroid hormone levels and current medication. The main goal is to see how many people respond positively to canvuparatide after 26 weeks. The current status of this study is unclear.
- Study design
- This is an interventional study comparing canvuparatide to a placebo, with a planned enrollment of 160 adult participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 26 weeks, suggesting follow-up for at least that duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
At a glance
Conditions
Where it's being run
2 sites across 2 statesWho to contact
What this trial measures
- To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.26 Weeks
Responder status is defined as a study participant who meets the following composite criteria: * Independence from active vitamin D * Independence from therapeutic doses of calcium (standing elemental calcium dose of ≤ 600 mg/day) * 2 consecutive albumin-adjusted serum calcium results in the normal range (8.3-10.6 mg/dL) (2.07-2.64 mmol/L) * No increase in study drug